Smart Money Is Betting Big In AMGN Options
Smart Money Is Betting Big In AMGN Options
Investors with a lot of money to spend have taken a bearish stance on Amgen (NASDAQ:AMGN).
資金雄厚的投資者對安進（納斯達克：AMGN）持看淡態度。
And retail traders should know.
零售交易者應該知道。
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
我們在這裏追蹤的公開期權歷史記錄上看到交易時發現了這一點。
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
不管這些投資者是機構還是富有的個人，我們不得而知。但當AMGN發生如此重大的事件時，通常意味着有人知道即將發生的事情。
So how do we know what these investors just did?
那麼我們如何知道這些投資者剛剛做了什麼呢？
Today, Benzinga's options scanner spotted 27 uncommon options trades for Amgen.
今日，Benzinga的期權掃描器發現了27筆不常見的安進期權交易。
This isn't normal.
這不正常。
The overall sentiment of these big-money traders is split between 37% bullish and 55%, bearish.
這些大單交易的整體情緒在看好和看淡之間分爲37%和55%。
Out of all of the special options we uncovered, 5 are puts, for a total amount of $163,558, and 22 are calls, for a total amount of $1,426,699.
在我們發現的所有特殊期權交易中，有5個看跌期權，總金額爲163,558美元，22個看漲期權，總金額爲1,426,699美元。
Predicted Price Range
預測價格區間
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $340.0 for Amgen over the recent three months.
根據交易活動，看起來這些重要投資者在過去三個月內瞄準了一個價格區間，從230.0美元到340.0美元的安進。
Volume & Open Interest Development
成交量和持倉量的評估是期權交易中的一個關鍵步驟。這些指標揭示了阿里巴巴集團（Alibaba Gr Hldgs）特定執行價格期權的流動性和投資者興趣。下面的數據可視化了在過去30天內，阿里巴巴集團（Alibaba Gr Hldgs）在執行價格在74.0美元到120.0美元區間內的看漲看跌期權中，成交量和持倉量的波動情況。
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 1080.41 with a total volume of 2,179.00.
就流動性和興趣而言，安進期權交易今天的平均持倉量爲1080.41，總成交量爲2,179.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $230.0 to $340.0 over the last 30 days.
在下面的圖表中，我們可以追蹤過去30天內安進看漲和看跌期權的交易量和持倉量，這些期權的行權價格區間在230.0美元到340.0美元之間。
Amgen 30-Day Option Volume & Interest Snapshot
安進30天期權成交量和持倉量快照
Biggest Options Spotted:
最大的期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BULLISH | 06/28/24 | $12.5 | $11.4 | $12.5 | $312.50 | $188.7K | 283 | 50 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $57.25 | $54.5 | $56.15 | $280.00 | $174.0K | 1.7K | 21 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $57.1 | $54.5 | $56.15 | $280.00 | $140.3K | 1.7K | 65 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $56.4 | $54.15 | $55.85 | $280.00 | $106.1K | 1.7K | 2 |
| AMGN | CALL | SWEEP | BULLISH | 07/19/24 | $10.15 | $8.95 | $10.15 | $320.00 | $101.5K | 2.4K | 4 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看漲 | SWEEP | 看好 | 06/28/24 | $12.5 | $11.4 | $12.5 | $312.50 | $188.7K | 283 | 50 |
| AMGN | 看漲 | 交易 | 看好 | 01/17/25 | $57.25 | $54.5 | $56.15 | $280.00 | $174.0K | 1.7K | 21 |
| AMGN | 看漲 | 交易 | 看好 | 01/17/25 | $57.1 | $54.5 | $56.15 | $280.00 | $140.3K | 1.7K | 65 |
| AMGN | 看漲 | 交易 | 看好 | 01/17/25 | $56.4 | $54.15 | $55.85 | $280.00 | $106.1K | 1.7K | 2 |
| AMGN | 看漲 | SWEEP | 看好 | 07/19/24 | $10.15 | $8.95 | $10.15 | $320.00 | $101.5千 | 2.4K | 4 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
Amgen's Current Market Status
安進當前市場狀態
- With a trading volume of 1,172,634, the price of AMGN is up by 0.34%, reaching $319.24.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 37 days from now.
- 安進（AMGN）的交易量爲1,172,634，價格上漲0.34%，達到319.24美元。
- 當前RSI值表明股票可能已經超買。
- 下一個盈利報告將在 37 天后發佈。
What Analysts Are Saying About Amgen
分析師對安進的評論
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $332.0.
過去一個月中，有1位行業分析師分享了他們對該股票的見解，提出了332.0美元的平均目標價。
- Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Amgen, targeting a price of $332.
- RBC Capital的一位分析師維持了對安進的推薦評級，並以$332.0的價格爲目標。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。